Table 2.
Relative risks and 95% confidence intervals from network meta-analysis of omega-3 supplementation, statins, and placebo effects on all-cause mortality and cardiovascular disease death.
| Comparison | All-Cause Mortality | Cardiovascular Disease Death |
|---|---|---|
| Overall | ||
| Statins vs. placebo | 0.88 (0.84–0.93) | 0.84 (0.78–0.91) |
| Omega-3 vs. placebo | 0.97 (0.92–1.03) | 0.91 (0.84–0.99) |
| Statins vs. omega-3 | 0.91 (0.85–0.98) | 0.92 (0.82–1.04) |
| Primary prevention | ||
| Statins vs. placebo | 0.89 (0.78–1.01) | 0.77 (0.65–0.93) |
| Omega-3 vs. placebo | 0.97 (0.91–1.03) | 0.91 (0.81–1.03) |
| Statins vs. omega-3 | 0.92 (0.80–1.06) | 0.85 (0.68–1.05) |
| Secondary prevention | ||
| Statins vs. placebo | 0.93 (0.84–1.04) | 0.90 (0.66–1.22) |
| Omega-3 vs. placebo | 0.95 (0.87–1.04) | 0.93 (0.78–1.10) |
| Statins vs. omega-3 | 0.98 (0.85–1.13) | 0.97 (0.66–1.43) |
| Mixed population | ||
| Statins vs. placebo | 0.87 (0.81–0.93) | 0.84 (0.76–0.93) |
| Omega-3 vs. placebo | 0.98 (0.88–1.10) | 0.91 (0.76–1.09) |
| Statins vs. omega-3 | 0.88 (0.77–1.01) | 0.92 (0.75–1.14) |
Bold font indicates statistical significance.